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Aims Spironolactone up-titration may be limited by side effects that could be minimized at lower than target doses,
but whether lower than target doses remain efficacious is unknown. In TOPCAT, spironolactone (or placebo)
were started at 15 mg/day, and increased up to a maximum of 45 mg/day. The prognostic implications related to
spironolactone dose are yet to be reported. We aimed to assess the average spironolactone/placebo doses provided
during the trial, overall and within high-risk subgroups (e.g. elderly, renal dysfunction, high potassium); discontinuation
rates; and the efficacy of lower than target doses in heart failure with preserved ejection fraction.
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Methods
and results
Overall, 1767 patients from ‘TOPCAT-Americas’ were included. Linear, logistic and Cox regressions were
applied. Patients randomized to spironolactone received lower doses than placebo: 22.5 (15.0–27.5) mg/day
vs. 27.5 (17.5–27.5) mg/day (P< 0.001). Patients aged ≥75 years, with an estimated glomerular filtration
rate ≤60 mL/min/1.73 m2, and with potassium levels >4.5 mmol/L, received lower spironolactone doses
(median≈ 20 mg/day). This pattern of dose differences was not observed in patients taking placebo, where
the between-subgroup placebo doses were similar (spironolactone–placebo by subgroup Pinteraction < 0.05). Among
patients taking spironolactone, 25.4% discontinued the drug during the first year, compared with 18.3% of the patients
taking placebo (P< 0.001). Discontinuation rates in the aforementioned high-risk subgroups reached 30% during
the first year. Spironolactone reduced the primary outcome of heart failure hospitalization/cardiovascular death
without significant heterogeneity between the study subgroups (Pinteraction > 0.1). Spironolactone discontinuation was
associated with a two to fourfold higher risk of subsequent events.
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Conclusion Spironolactone (but not placebo) was used at lower doses among the elderly, those with renal dysfunction and with
higher potassium levels. The effect of spironolactone was homogeneous across these subgroups. In patients unable
to tolerate target doses, a low-dose strategy should be preferred to stopping treatment.
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Introduction
The updated American College of Cardiology/American Heart
Association/Heart Failure Society of America heart failure (HF)
guidelines give spironolactone a class of recommendation IIb (‘weak
benefit’) with a B-R (‘moderate-quality randomized evidence’)
level of evidence for treating patients with HF and preserved
ejection fraction (HFpEF) in the absence of contraindications.1
This recommendation is based upon the results of the TOPCAT
(Treatment of Preserved Cardiac Function Heart Failure with an
Aldosterone Antagonist) trial that compared spironolactone with
placebo in HFpEF, showing a small reduction in the primary com-
posite outcome of cardiovascular death, aborted cardiac arrest,
and HF hospitalization, not reaching statistical significance, but
showing a reduction in HF hospitalizations.2 Importantly, major
geographical variations were found in TOPCAT, whereby patients
randomized in Eastern Europe had low event rates, no spirono-
lactone effect on blood pressure or potassium (K+) levels, and
low or non-detectable levels of spironolactone metabolites in the
blood.3–6 In a post hoc analysis with patients from ‘the Ameri-
cas’, spironolactone effectively reduced the rate of the primary
outcome and its individual components including cardiovascular
death.3
In TOPCAT, spironolactone (or placebo) were started at a dose
of 15 mg/day, and after 4 weeks, the dose should be increased
to 30 mg/day if all safety parameters were acceptable. In the
event that the subject continued to have ongoing HF symp-
toms, the investigator had the option to increase the dose up to
45 mg/day at 4 months.2 In patients with HF with reduced ejec-
tion fraction (HFrEF) and based on findings from RALES (Ran-
domized Aldactone Evaluation Study),7 current guidelines rec-
ommend spironolactone doses of 25 mg/day, titrated and main-
tained at 50 mg/day whenever possible. The corresponding main-
tenance dose of eplerenone is 50 mg/day.1,8 In the EMPHASIS-HF
(Eplerenone in Mild Patients Hospitalization and Survival Study in
Heart Failure) trial, eplerenone dose was stratified according to
renal function, where patients with an estimated glomerular filtra-
tion rate (eGFR) <50 mL/min/1.73 m2 received up to 25 mg/day
of eplerenone, whereas patients with higher eGFR received up
to 50 mg/day.9 This stratified analysis showed that the treatment
effect was consistent regardless of the eGFR dose stratum, still
more patients with impaired renal function experienced more side
effects, such as hyperkalaemia, despite receiving lower eplerenone
doses.10
After TOPCAT, guidelines do not provide specific dose recom-
mendations for HFpEF; however, it may be assumed that the doses
should be within the dose range used in TOPCAT, i.e. between 15
and 45 mg/day.1 These doses are not currently commercialized and
in TOPCAT some patient subgroups might have received low doses
and/or have experienced more adverse events.
In this study, we sought to assess the spironolactone (and
placebo) dose provided during the trial, overall and within sub-
groups of interest (e.g. elderly, female, those with renal impair-
ment or higher baseline K+ levels). Additionally, we aim to assess
the discontinuation rates and treatment effects. The background



















































































.. lower spironolactone doses and, despite this, had similar treatment
benefit, then one can hypothesize that the minimum tolerated dose
is better than stopping treatment or force up-titration, which may
increase side effects and drug discontinuation.
Methods
Study design and participants
The detailed methods of TOPCAT have been previously described.2
In short, TOPCAT enrolled 3445 patients with symptomatic HF and
a left ventricular ejection fraction (LVEF) ≥45% who were randomly
assigned to spironolactone (15–45 mg/day) or matching placebo. The
primary outcome was a composite of death from cardiovascular
causes, aborted cardiac arrest, or hospitalization for the manage-
ment of HF.2 The median (pct25–75) follow-up time was 2.9 (1.9–4.2)
years.
TOPCAT was conducted in accordance with the Declaration of
Helsinki and approved by all site ethics committees. All participants
gave written informed consent to participate in the study.
In TOPCAT the patient subset who both had event rates compatible
with HFpEF, had spironolactone side effects and adequate levels of
spironolactone circulating metabolites were those from ‘the Americas’;
hence, consistently with previous reports, this analysis is limited to this
subset (n = 1767).3,4,11,12
Subgroups of interest
The following subgroups were selected for dose comparison: sex was
chosen because a recent observational report suggesting that women
with HF could respond to lower doses of angiotensin-converting
enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) and
beta-blockers compared to men13; age, renal function, diabetes, and
baseline K+ levels were selected because these are identified ‘high-risk’
subgroups who may be prone to adverse events from mineralocorti-
coid receptor antagonist (MRA) therapy14–16; body mass index, blood
pressure and ACEi/ARB treatment were also selected due to their
potential influence on prognosis and MRA dose.17–20
Statistical analyses
Spironolactone and placebo doses were summarized with medians,
means and the respective 25th–75th percentile range and standard
deviations (SD). The average dose was obtained by computing the sum
of the spironolactone doses for each patient at each study visit and
dividing it by the number of study visits. For the between-group com-
parison of the doses, Mann–Whitney rank-sum tests were used. To
assess if the differences of the doses were different across the sub-
groups of interest, we performed an interaction test from a linear
regression model with the spironolactone or placebo dose as depen-
dent variable and the subgroup plus an interaction term of treatment
by subgroup as independent variables. We report the mean doses dur-
ing the first year of follow-up for each patient as only about 10%
of missing dose values were present during this time period; the
doses during the entire follow-up are also presented in the supple-
mentary material; however, the proportion of missing values greatly
increased after the first follow-up year (online supplementary Table S1).
The proportion of spironolactone or placebo discontinuation and the
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Table 1 Drug dose during 1-year follow-up
Placebo dose (mg/day) Spironolactone dose (mg/day) Pinteraction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Median (pct25–75) Mean±SD Median (pct25–75) Mean±SD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall (n = 1767) 27.5 (17.5–27.5) 23.9± 8.6 22.5 (15.0–27.5) 21.1± 9.3 –
Placebo vs. spironolactone P-value <0.001
Sex
Male (n = 885) 27.5 (17.5–27.5) 23.6± 8.7 22.5 (15.0–27.5) 21.4± 9.1 0.23
Female (n = 882) 27.5 (20.0–27.5) 24.2± 8.5 22.5 (15.0–27.5) 20.9± 9.5
Male vs. female P-value 0.40 0.51
Age
<75 years (n = 1020) 27.5 (17.5–27.5) 24.0± 8.3 25.0 (15.0–27.5) 22.1± 9.0 0.016
≥75 years (n = 747) 27.5 (17.5–27.5) 23.8± 9.0 20.0 (15.0–27.5) 19.9± 9.6
<75 vs. ≥75 years P-value 0.99 <0.001
eGFR
≤60 mL/min (n = 854) 27.5 (17.5–27.5) 23.3± 8.6 20.0 (12.5–27.5) 19.1± 9.1 0.002
>60 mL/min (n = 912) 27.5 (20.0–30.0) 24.5± 8.5 26.6 (15.0–27.5) 23.0± 9.2
≤60 vs. >60 mL/min P-value 0.027 <0.001
Diabetes
No diabetes (n = 788) 27.5 (20.0–27.5) 24.1± 8.6 22.5 (15.0–27.5) 21.3± 9.3 0.81
Diabetes (n = 977) 27.0 (17.5–27.5) 23.7± 8.6 22.5 (15.0–27.5) 20.9± 9.5
No diabetes vs. diabetes P-value 0.17 0.48
Potassium
≤4.5 mmol/L (n = 1389) 27.5 (17.5–27.5) 24.0± 8.7 24.0 (15.0–27.5) 21.7± 9.1 0.011
>4.5 mmol/L (n = 377) 27.5 (17.5–27.5) 23.6± 8.3 17.5 (12.5–27.5) 18.7±10.0
≤4.5 vs. >4.5 mmol/L P-value 0.60 0.001
Body mass index
≤30 kg/m2 (n = 623) 27.5 (17.5–27.5) 23.1± 8.5 20.0 (15.0–27.5) 20.1± 9.1 0.52
>30 kg/m2 (n =1135) 27.5 (20.0–30.0) 24.4± 8.6 25.0 (15.0–27.5) 21.7± 9.4
≤30 vs. >30 kg/m2 P-value 0.039 0.004
Systolic blood pressure
≤120 mmHg (n = 615) 27.0 (16.3–27.5) 23.4± 8.8 22.5 (15.0–27.5) 21.1± 9.4 0.34
>120 mmHg (n = 1149) 27.5 (18.8–27.5) 24.2± 8.5 22.5 (15.0–27.5) 21.1± 9.3
≤120 vs. >120 mmHg P-value 0.10 0.95
ACEi/ARB treatment
No ACEi/ARB (n = 381) 27.5 (17.5–27.5) 23.6± 8.6 22.5 (15.0–27.5) 21.3± 9.3 0.60
ACEi/ARB (n = 1385) 27.5 (18.8–27.5) 24.0± 8.6 22.5 (15.0–27.5) 21.1± 9.4
No ACEi/ARB vs. ACEi/ARB P-value 0.74 0.81
Values are given as median (25th–75th percentile) and mean± SD.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; SD, standard deviation.
P-values are derived from a Mann–Whitney rank-sum test (with similar results from the Student’s t-test); the interaction test is derived from a linear regression model.
studied side effects are reported with absolute numbers and propor-
tions and compared using Chi-square tests. To assess if the differ-
ences in discontinuation and side effects found between the subgroups
of interest were statistically significant, we performed an interaction
test from a logistic regression model with discontinuation or side
effect as dependent variable and the subgroup plus a treatment by
subgroup interaction term as independent variables. Logistic regres-
sion models were used to assess the determinants of spironolactone
up-titration during the first month. Cox proportional hazards models
were used to explore the association between spironolactone treat-
ment and the study primary outcome. The treatment effect estimates
are presented with hazard ratios (HRs) and their respective 95% con-
fidence interval (95% CI). To assess whether the treatment effect
could vary by subgroup of interest, we performed interaction tests





















.. models were used to study the associations between spironolactone
(or placebo) discontinuation and subsequent outcomes. Landmark
analyses were performed to assess the association between spirono-
lactone (or placebo) 4-week up-titration and subsequent outcomes.
Statistical analyses were performed using the STATA/SE software, ver-
sion 16.0 (Stata Corp, College Station, TX, USA).
Results
Spironolactone and placebo doses
As previously reported,3 the median age was 72 (64–79) years,
41% were aged ≥75 years, 50% were female, the median body
mass index (BMI) was 32 (28–38) kg/m2, 45% had diabetes, 79%
were treated with an ACEi/ARB, 48% had chronic kidney disease,
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Figure 1 Profile plot of spironolactone vs. placebo dose
throughout the follow-up. Representation of the spironolactone
and placebo doses (in mg/day) over time.
the median eGFR was 61 (49–77) mL/min/1.73 m2, the median
K+ was 4.2 (3.9–4.5) mmol/L, the median systolic blood pressure
(SBP) was 129 (118–138) mmHg, and the median LVEF was 58
(53–64)%.
Patients randomized to spironolactone received lower doses
than placebo. Overall, the median (pct25–75)/mean± SD dose dur-
ing 1-year follow-up was 27.5 (17.5–27.5)/23.9± 8.6 mg/day in
the placebo group vs. 22.5 (15.0–27.5)/21.1± 9.3 mg/day in the
spironolactone group (P< 0.001) (Table 1, Figure 1 and online sup-
plementary Figure S1).
In subgroups, women and men, diabetics and non-diabetics,
those with a SBP below or above 120 mmHg, and those taking
or not an ACEi/ARB received similar spironolactone and placebo
doses (Table 1). Patients with a BMI ≤30 kg/m2 received lower
spironolactone doses than those with a BMI >30 kg/m2; but with-
out significant statistical heterogeneity vs. patients receiving a
placebo (Pinteraction = 0.52). Patients, aged ≥75 years, with an eGFR
≤60 mL/min/1.73 m2, and those with a baseline K+ >4.5 mmol/L,
received lower spironolactone doses than patients aged <75 years,
with an eGFR >60 mL/min/1.73 m2, and with a K+ ≤4.5 mmol/L,
respectively; with significant heterogeneity vs. patients receiving
placebo (Pinteraction < 0.05).
In patients taking placebo, the between-subgroup placebo doses
were similar and the dose difference pattern observed in patients
taking spironolactone was not observed in those taking the corre-
sponding placebo (Table 1 and Figure 2).
Similar findings were observed during the first year at equally
spaced time-points (4, 8 and 12 months) (online supplementary
Table S2), and throughout the entire follow-up, where even lower
doses were administered (online supplementary Table S3). (It
should be noted that these findings including data from the entire
follow-up period may be biased by a large proportion of missing




















































































Figure 2 Spironolactone dose by subgroups over time. (A) Age.
(B) Estimated glomerular filtration rate (eGFR). (C) Potassium
(K+). The y-axis represents the mean treatment dose in mg/day;
the treatment by subgroup Pinteraction is <0.05 for all the repre-
sented subgroups (see also Table 1).
Spironolactone and placebo
discontinuation
Among patients taking spironolactone, 25.4% discontinued the
drug during the first year of the trial, compared with 18.3% of
patients taking placebo (P< 0.001) (Table 2). Again, patients aged
≥75 years, and especially those with an eGFR ≤60 mL/min/1.73 m2,
and K+ >4.5 mmol/L were more likely to permanently stop the
drug, with discontinuation rates reaching 30% or more compared
with 18% in the placebo group (Pinteraction < 0.05 for eGFR and K
+)
(Table 2).
The main reported discontinuation reasons were hyperkalaemia,
worsening renal function (WRF) and off-label MRA use (online
supplementary Table S4).
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Overall (n = 1767) 161 (18.3) 225 (25.4) –
Placebo vs. spironolactone P-value – <0.001
Sex
Male (n = 885) 85 (19.3) 114 (25.7) 0.65
Female (n = 882) 76 (17.3) 111 (25.1)
Male vs. female P-value 0.44 0.85
Age
<75 years (n = 1020) 96 (18.3) 114 (23.1) 0.25
≥75 years (n = 747) 65 (18.3) 111 (28.1)
<75 vs. ≥75 years P-value 0.98 0.075
eGFR
≤60 mL/min (n = 854) 77 (17.8) 125 (29.6) 0.036
>60 mL/min (n = 912) 84 (18.9) 100 (21.6)
≤60 vs. >60 mL/min P-value 0.72 0.006
Diabetes
No diabetes (n = 788) 84 (17.4) 118 (23.8) 0.82
Diabetes (n = 977) 77 (19.4) 107 (27.4)
No diabetes vs. diabetes P-value 0.45 0.23
Potassium
≤4.5 mmol/L (n = 1389) 126 (18.6) 167 (23.5) 0.043
>4.5 mmol/L (n = 377) 35 (17.3) 58 (33.1)
≤4.5 vs. >4.5 mmol/L P-value 0.69 0.009
Body mass index
≤30 kg/m2 (n = 623) 59 (18.5) 82 (27.0) 0.59
>30 kg/m2 (n = 1135) 102 (18.4) 141 (24.3)
≤30 vs. >30 kg/m2 P-value 0.97 0.39
Systolic blood pressure
≤120 mmHg (n = 615) 54 (17.1) 71 (23.8) 0.99
>120 mmHg (n = 1149) 107 (19.0) 153 (26.1)
≤120 vs. >120 mmHg P-value 0.48 0.44
ACEi/ARB treatment
No ACEi/ARB (n = 381) 36 (19.5) 43 (21.9) 0.23
ACEi/ARB (n = 1385) 125 (18.0) 182 (26.4)
No ACEi/ARB vs. ACEi/ARB P-value 0.65 0.21
Values are given as numbers and proportions (%).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.
P-values are derived from a Chi2 test; the interaction test is derived from a logistic regression.
Determinants of treatment up-titration
at 4 weeks
During the first month, 531 (30.0%) of patients were not
up-titrated to 30 mg/day. Patients without successful up-titration
were more likely to be older, have lower eGFR, a BMI ≤30 kg/m2,
and a SBP ≤120 mmHg (online supplementary Table S5). Patients
without successful up-titration did not experience higher event
rate, nor the risk was modified by the randomized treatment
allocation (spironolactone or placebo) (online supplementary
Table S6).
Treatment effect
As previously reported,3 spironolactone reduced the pri-
























. without significant heterogeneity between the study subgroups
(Pinteraction > 0.1 for all) (online supplementary Table S7).
Side effects
Patients taking spironolactone experienced more often WRF and
hyperkalaemia episodes during the follow-up. Diabetes was a risk
factor for both WRF and hyperkalaemia. Females also had more
WRF episodes; and patients with eGFR ≤60 mL/min/1.73 m2, those
with baseline K+ >4.5 mmol/L, those taking ACEi/ARB and with
SBP >120 mmHg also had more hyperkalaemia episodes (Table 3).
Time-updated outcomes after treatment
discontinuation
Treatment discontinuation was associated with a two to fourfold
higher risk of major cardiovascular events in adjusted models
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall (n =1767) –
Worsening renal function 289 (32.8) 389 (43.9)
Placebo vs. spironolactone P-value – <0.001
Hyperkalaemia 46 (5.2) 141 (15.9)
Placebo vs. spironolactone P-value – <0.001
Sex
Worsening renal function
Male (n = 885) 129 (29.3) 175 (39.4) 0.81
Female (n = 882) 160 (36.4) 214 (48.5)
Male vs. female P-value 0.025 0.006
Hyperkalaemia
Male (n = 885) 22 (5.0) 73 (16.5) 0.63
Female (n = 882) 24 (5.5) 68 (15.4)
Male vs. female P-value 0.76 0.66
Age
Worsening renal function
<75 years (n = 1020) 179 (34.0) 217 (43.9) 0.48
≥75 years (n = 747) 110 (31.0) 172 (44.0)
<75 vs. ≥75 years P-value 0.35 0.99
Hyperkalaemia
<75 years (n = 1020) 27 (5.2) 74 (15.0) 0.73
≥75 years (n = 747) 19 (5.4) 67 (17.2)
<75 vs. ≥75 years P-value 0.90 0.38
eGFR
Worsening renal function
≤60 mL/min (n = 854) 147 (34.0) 188 (44.7) 0.76
>60 mL/min (n = 912) 141 (31.5) 201 (43.3)
≤60 vs. >60 mL/min P-value 0.42 0.69
Hyperkalaemia
≤60 mL/min (n = 854) 30 (6.9) 97 (23.0) 0.35
>60 mL/min (n = 912) 16 (3.6) 44 (9.5)
≤60 vs. >60 mL/min P-value 0.026 <0.001
Diabetes
Worsening renal function
No diabetes (n = 788) 141 (29.3) 198 (40.1) 0.98
Diabetes (n = 977) 147 (37.0) 191 (48.9)
No diabetes vs. diabetes P-value 0.015 0.009
Hyperkalaemia
No diabetes (n = 788) 20 (4.2) 64 (13.0) 0.94
Diabetes (n = 977) 26 (6.6) 77 (20.0)
No diabetes vs. diabetes P-value 0.12 0.006
Potassium
Worsening renal function
≤4.5 mmol/L (n = 1389) 215 (31.7) 323 (45.5) 0.032
>4.5 mmol/L (n = 377) 73 (36.1) 66 (37.7)
≤4.5 vs. >4.5 mmol/L P-value 0.24 0.063
Hyperkalaemia
≤4.5 mmol/L (n = 1389) 22 (3.3) 90 (12.7) 0.35
>4.5 mmol/L (n = 377) 24 (11.9) 51 (29.3)
≤4.5 vs. >4.5 mmol/L P-value <0.001 <0.001
Body mass index
Worsening renal function
≤30 kg/m2 (n = 623) 94 (29.5) 131 (43.2) 0.40
>30 kg/m2 (n = 1135) 191 (34.4) 258 (44.5)
≤30 vs. >30 kg/m2 P-value 0.13 0.72
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Hyperkalaemia
≤30 kg/m2 (n = 623) 13 (4.1) 51 (16.8) 0.25
>30 kg/m2 (n = 1135) 32 (5.8) 90 (15.6)
≤30 vs. >30 kg/m2 P-value 0.28 0.65
Systolic blood pressure
Worsening renal function
≤120 mmHg (n = 615) 88 (27.9) 117 (39.1) 0.80
>120 mmHg (n = 1149) 200 (35.5) 272 (46.5)
≤120 vs. >120 mmHg P-value 0.020 0.037
Hyperkalaemia
≤120 mmHg (n = 615) 16 (5.1) 47 (15.7) 0.95
>120 mmHg (n = 1149) 30 (5.3) 94 (16.1)
≤120 vs. >120 mmHg P-value 0.87 0.88
ACEi/ARB treatment
Worsening renal function
No ACEi/ARB (n = 381) 61 (33.0) 77 (39.3) 0.28
ACEi/ARB (n = 1385) 227 (32.7) 312 (45.3)
No ACEi/ARB vs. ACEi/ARB P-value 0.94 0.13
Hyperkalaemia
No ACEi/ARB (n = 381) 13 (7.1) 22 (11.2) 0.027
ACEi/ARB (n = 1385) 33 (4.8) 119 (17.3)
No ACEi/ARB vs. ACEi/ARB P-value 0.21 0.040
Values are given as numbers and proportions (%).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.
Worsening renal function defined as any eGFR drop >30% from the baseline value during the follow-up.
Hyperkalaemia defined as any potassium measurement >5.5 mmol/L during the follow-up.
P-values are derived from a Chi2 test; the interaction test is derived from a logistic regression.
(Table 4). Compared with placebo, the risk was higher after
spironolactone discontinuation, although the interaction test
did not reach statistical significance. Primary outcome example:
HR (95% CI) for placebo = 1.63 (1.22–2.18) and HR (95%
CI) for spironolactone = 2.28 (1.72–3.02); Pinteraction = 0.13
(Table 4).
Discussion
The present study shows that spironolactone (but not placebo)
was used at lower doses among the elderly, those with impaired
renal function and with higher K+ levels at baseline. Most of these
patients received around 20 mg/day of spironolactone within the
first year of follow-up, and around 15 mg/day if one considers the
entire follow-up. These patients had more adverse events and dis-
continued the treatment more often. Nonetheless, the effect of
spironolactone was homogeneous across these subgroups. These
findings suggest that spironolactone doses <25 mg/day (around
15–20 mg/day) may be used in HFpEF, particularly in high-risk
patients that may not tolerate higher doses. Keeping the patients
on treatment (even with lower than recommended doses) seems
preferable to stopping treatment, as the latter may increase the
risk of subsequent events. It should also be highlighted that other




































. treatment/no-ACEi/ARB treatment received similar spironolac-
tone doses.
Differently from ACEi/ARBs and 𝛽-blockers in which random-
ized trials compared different doses of these drugs,21–26 no tri-
als have compared different MRA doses. So far, the best avail-
able evidence comes from the EMPHASIS-HF trial, where patients
were stratified to different eplerenone or placebo doses accord-
ing to renal function.10 Despite receiving lower eplerenone or
placebo doses, patients with impaired renal function experienced
more side effects; however, the treatment effect was not modified
by treatment dose/renal function (Pinteraction = 0.89). Hence, this
stratified evidence strongly support the use of lower (≈25 mg/day)
eplerenone doses in patients with HFrEF and impaired renal func-
tion. This way, the beneficial effect of treatment is preserved, while
excessive dose-related side effects can be potentially avoided. Sec-
ondary non-stratified analyses of the TOPCAT trial suggest that
elderly patients, those with impaired renal function and higher
K+ levels experience more adverse events and have higher rates
of drug discontinuation without treatment effect heterogeneity
between these subgroups.11,27 The data depicted in the present
report show that the spironolactone doses given to the elderly, to
those with impaired renal function and with higher baseline K+ are
lower than the doses given to the younger, with better renal func-
tion and with lower K+ levels. Importantly, the placebo doses were
© 2020 European Society of Cardiology
1622 J.P. Ferreira et al.









HR (95% CI) P-value Pinteraction*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV death or HFH (n = 522) 348 (2.9) 174 (5.1) 1.88 (1.55–2.29) <0.001 0.13
CV death (n = 223) 106 (0.8) 117 (2.7) 2.76 (2.08–3.66) <0.001 0.15
ACM (n = 387) 154 (1.2) 233 (5.4) 3.76 (3.02–4.67) <0.001 0.32
ACM, all-cause mortality; CI, confidence interval; CV, cardiovascular; HFH, heart failure hospitalization; HR, hazard ratio.
All models adjusted for age, sex, body mass index, systolic blood pressure, diabetes, atrial fibrillation, previous myocardial infarction, estimated glomerular filtration rate,
potassium, and use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
*P-value for interaction between drug discontinuation and spironolactone or placebo allocation.
HR (95%CI) for the placebo and spironolactone groups:
– CV death or HFH: HR (95% CI) 1.63 (1.22–2.18) and 2.28 (1.72–3.02) for placebo and spironolactone, respectively.
– CV death: HR (95% CI) 2.45 (1.69–3.56) and 3.60 (2.29–5.65) for placebo and spironolactone, respectively.
– ACM: HR (95% CI) 3.56 (2.64–4.77) and 4.38 (3.13–6.12) for placebo and spironolactone, respectively.
similar between these subgroups, strongly supporting the inabil-
ity for titrating spironolactone to higher doses due to side effects
and intolerance. During the first year of follow-up, the median
dose among these high-risk subgroups was around 20 mg/day; and,
importantly, treatment discontinuation rates reached nearly 30%
for spironolactone vs. 18% for placebo in these subgroups. Dis-
continuation rates reaching 30% of the patients may seriously com-
promise the treatment effect that is aimed to improve medium to
long-term outcomes, including repeat hospitalizations.28 Further-
more, spironolactone discontinuation was associated with a sub-
sequent high rate of adverse cardiovascular events. These findings
support the continuation of spironolactone, even at lower doses
(15–20 mg/day) if patients cannot tolerate higher doses. Further-
more, patients without successful up-titration during the 4-week
optimization period did not experience higher event rates, nor the
risk was modified by the randomized treatment allocation, sup-
porting the notion that lower than target doses may also be effec-
tive. Strategies aimed at enabling an adequate drug maintenance
and potential up-titration of renin–angiotensin–aldosterone sys-
tem inhibitors, such as K+ binders,29 may be important to improve
outcomes of HF patients; however, adequately powered outcome
trials to assess the efficacy and safety of such a strategy are yet
to be performed.30 Furthermore, newer generation MRAs may be
better tolerated than spironolactone.31 However, these molecules
also need to show that they are, at least, non-inferior to spirono-
lactone. Despite these advances, it is likely that spironolactone will
remain the most widely used MRA, mainly because it is affordable,
widely available, and with a large and long clinical experience.32
Still, MRAs are generally underused, even in populations who might
experience great benefit.33 With regard to dose adaptations, and
until further evidence is available, it seems reasonable to adapt
the spironolactone dose according to renal function and K+ lev-
els based on an algorithm that has been used in clinical trials
(online supplementary Table S8). Notwithstanding, the data sug-
gest that having lower spironolactone dose is better than stopping


























































This is a post-hoc analysis of a randomized controlled trial, thus
these findings are subject to the bias of observational studies, such
as the impossibility of inferring causality. From the case repord
forms we could not ascertain the exact reasons for study discontin-
uation in all patients; however, the provided reasons (e.g. renal dys-
function and hyperkalaemia) are expected and consistent with the
previous reports. From these data, one cannot infer which spirono-
lactone dose is more adequate; one can only say that many patients
did not reach the target of dose of 45 mg/day, especially among
those in the aforementioned high-risk subgroups that received
less than half of the recommended dose. As the treatment effect
was consistent in these subgroups, one may suppose that lower
doses are probably as efficient and could avoid some side effects.
Contrary to the EMPHASIS-HF trial (that had a pre-specified
eplerenone dose stratification by renal function),10 the TOPCAT
trial assumed a priori that all patients should achieve similar spirono-
lactone (or placebo) doses, hence the findings reported herein do
not represent randomized evidence and should be regarded as
hypothesis-generating. The association of spironolactone discon-
tinuation with subsequent outcomes likely reflects the underlying
patient risk rather than the direct treatment effect and, therefore,
causality cannot be inferred. This study does not compare ‘high
vs. low’ doses, instead it simply reports the ‘average’ doses. To
ascertain the optimal spironolactone dose for patients with HFpEF
(including the dose for high-risk subgroups), prospective, random-
ized and adequately powered studies will be required.
Conclusions
Spironolactone (but not placebo) was used at lower doses among
the elderly, those with impaired renal function and higher K+ levels
at baseline. Most of these patients received around 20 mg/day of
spironolactone within the first year of follow-up, which was less
than half of the target dose. These patients had more adverse
events and discontinued the treatment more often. Despite the
lower treatment doses and higher discontinuation rates, the effect
© 2020 European Society of Cardiology
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of spironolactone was homogeneous across these subgroups.
These findings suggest that patients unable to tolerate target doses
of spironolactone may benefit from lower doses that are possi-
bly better tolerated while maintaining efficacy. A low-dose strategy
should be preferred to stopping the treatment.
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